GILD241129C91000
- 1.99
- +0.27+15.70%
Gilead Sciences Newsroom
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here Is What You Need to Know
RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD)
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Express News | Gilead Announces New England Journal of Medicine Publication of Purpose 2 Results
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Gilead Acquires Investigational HIV Vaccine From Spanish Biotech Aelix
Price Over Earnings Overview: Gilead Sciences
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
3 'Buy' Stocks and 2 'Hold' Stocks According to Oppenheimer
Express News | ubs group has raised the target price of gilead sciences from $70.00 to $96.00.
Gilead Sciences Price Target Raised to $96.00/Share From $70.00 by UBS
Optimism Over Global Healthcare Sector Rises: Jefferies
UBS Initiates Gilead Sciences(GILD.US) With Hold Rating, Announces Target Price $96
Gilead Sciences Is Maintained at Outperform by Mizuho
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $100
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.
Express News | Bai'ao Zhihui has signed an asset purchase agreement with gilead sciences.
Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)